

### This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
<b>Cancer</b>				
Renal cancer	Src; von Hippel-Lindau tumor suppressor (vHL)	<p>A study in mice suggests inhibiting Src may help treat a subset of renal cell carcinomas. In mice with human renal cell carcinomas with wild-type vHL expression, Sprycel dasatinib decreased tumor growth compared with vehicle. Mice with renal cell carcinomas that had low vHL expression showed no change in tumor growth when given Sprycel. Next steps include looking at the effects of therapeutic combinations involving Sprycel in preclinical models of vHL-positive renal cell carcinoma.</p> <p>Bristol-Myers Squibb Co. and Otsuka Pharmaceutical Co. Ltd. market the dual BCR-ABL tyrosine kinase and Src inhibitor Sprycel for acute lymphoblastic leukemia (ALL) and chronic myelogenous leukemia (CML). Bosutinib, a dual BCR-ABL tyrosine kinase and Src inhibitor from Pfizer Inc., is in Phase III testing for CML and Phase II testing for breast cancer.</p> <p><b>SciBX 4(24); doi:10.1038/scibx.2011.682</b>  <b>Published online June 16, 2011</b></p>	Patent and licensing status undisclosed	<p>Suwaki, N. <i>et al. Sci. Transl. Med.</i>; published online June 1, 2011; doi:10.1126/scitranslmed.3002004</p> <p><b>Contact:</b> George V. Thomas, Oregon Health &amp; Science University, Portland, Ore.            e-mail: <a href="mailto:thomasge@ohsu.edu">thomasge@ohsu.edu</a></p>